Deaya, Pfizer collaborate on clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ideaya Biosciences Inc. and Pfizer Inc. have formed a clinical trial collaboration and supply agreement.

The collaboration includes an Ideaya-sponsored clinical combination study of IDE196, a protein kinase C inhibitor—and binimetinib, a MEK inhibitor that Pfizer has exclusive rights to in the U.S. and Canada, in GNAQ or GNA11 hotspot mutated solid tumors, including metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer.

Ideaya and Pfizer will form a joint development committee, and there will be joint decision making and data sharing of the clinical trial results between the parties. Ideaya will sponsor the study, and Pfizer will supply binimetinib for the study. The clinical combination trial is targeted to initiate in mid-2020.

The clinical combination study will evaluate whether inhibition of the MAP-kinase pathway at two nodes, through upstream PKC and downstream MEK, will enhance the response rate and depth and durability of clinical benefit in patients whose solid tumors harbor GNAQ or GNA11 hotspot mutations. The clinical trial will also study pharmacokinetics of each agent and tolerability of the combination.

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login